Glenmark launches AKYNZEO® I.V. in India

Glenmark Pharmaceuticals Ltd is the first to launch in India a unique I.V. injection formulation, AKYNZEO® I.V., for the prevention of CINV, under an exclusive licensing agreement with Helsinn, a Swiss biopharma group company.

Related Keywords

Australia ,India ,Switzerland ,Swiss ,Alok Malik ,Giorgio Calderari ,National Cancer Registry Programme ,Glenmark Pharmaceuticals ,Helsinn Group ,Glenmark Pharmaceuticals Ltd ,Cancer Supportive Care ,Aprepitant Capsules ,Oral Capsules ,Glenmark Pharmaceuticals Limited ,Glenmarkpharmaceuticals ,Ine935a01035 ,Akynzeoiv ,Ivinjectionformulation ,Cinv ,Licensingagreement ,Helsinn ,